Mon panier

CD40

CD40 Informations sur la molécule

Nom anglaisTumor necrosis factor receptor superfamily member 5Nombre de médicaments commercialisés0
Nombre de médicaments cliniques46Alias de la cibleBp50,CD40 Antigens,CD40,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CDW40,CD40L Receptor,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,CD40 Molecule, TNF Receptor Superfamily Member 5,TNFRSF5,Tumor Necrosis Factor Receptor Superfamily Member 5,P50,CD40 Antigen,B Cell-Associated Molecule
Phase de R&D la plus avancéePhase 3 Clinical
Nom anglaisTumor necrosis factor receptor superfamily member 5
Alias de la cibleBp50,CD40 Antigens,CD40,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CDW40,CD40L Receptor,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,CD40 Molecule, TNF Receptor Superfamily Member 5,TNFRSF5,Tumor Necrosis Factor Receptor Superfamily Member 5,P50,CD40 Antigen,B Cell-Associated Molecule
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques46
Phase de R&D la plus avancéePhase 3 Clinical

CD40 Liste de produits

  • Attribut

    Protein (17)Cell (1)

  • Bibliothèque de produits

    En ligne (18)

  • Espèces

    Human (8)Rhesus macaque (2)Mouse (4)Cynomolgus (1)Rabbit (1)Rat (1)Canine (1)

  • Étiquette

    Fc Tag (4)His Tag (8)His Tag & Avi Tag (2)Fc Tag & Avi Tag (2)Mouse IgG Fc Tag (1)- (1)

  • Marqueur

    Unconjugated (12)Biotin-labeled (4)- (1)AF647 Labeled (1)

CD40Contexte de la molécule

CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

CD40Alias de la molécule

CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50

Coopération sous licence

Nom du projetType de médicamentDomain thérapeutiqueIndicationPhaseZone de droits
CD40 mAbMonospecific antibodyOncology/CancerAdvanced solid tumorPhase IGlobal

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
MitazalimabADC-1013; JNJ-7107; JNJ-64457107Phase 3 ClinicalAlligator Bioscience AbBiliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
CD40L-GVAXGM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSFPhase 2 ClinicalUniversity Of South FloridaAdenocarcinoma; Adenocarcinoma of Lung; Leukemia; Lung Neoplasms; Melanoma; Myelodysplastic Syndromes; Skin Melanoma
Details
BI-655064BI-655064Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. KgArthritis, Rheumatoid; Lupus Nephritis; Purpura, Thrombocytopenic, Idiopathic
Details
SotigalimabAPX-005M; EPI-0050; APX-005Phase 2 ClinicalEpitomics IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Microsatellite Instability; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Skin Neoplasms; Stomach Neoplasms
Details
IscalimabNVP-CFZ533; OM11-62-MF; CFZ-533Phase 2 ClinicalNovartis Pharma AgArthritis, Rheumatoid; Diabetes Mellitus, Type 1; Graves Disease; Hidradenitis Suppurativa; Lupus Erythematosus, Systemic; Lupus Nephritis; Myasthenia Gravis; Rejection of renal transplantation; Rejection of liver transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome
Details
Anti-CD40 ChiLob7/4 (BioNTech)Phase 2 ClinicalBiontech SeHead and Neck Neoplasms; Pancreatic Neoplasms
Details
CDX-1140CDX-1140Phase 2 ClinicalCelldex TherapeuticsBile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Mouth Neoplasms; Nasopharyngeal Carcinoma; Oral Squamous Cell Carcinoma; Oropharyngeal Neoplasms; Oropharyngeal Squamous Cell Carcinoma (OPSCC); Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uveal melanoma; Waldenstrom Macroglobulinemia
Details
Bleselumab4D-11; ASKP-1240Phase 2 ClinicalKyowa Hakko Kogyo Co LtdGlomerulosclerosis, Focal Segmental; Psoriasis; Rejection of renal transplantation; Rejection of organ transplantation
Details
TecaginlimabBNT-312; GEN-1042Phase 2 ClinicalGenmab A/SCarcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
MP-0317MP-0317Phase 2 ClinicalMolecular Partners AgBiliary Tract Neoplasms; Solid tumours
Details
ABBV-9832ABBV-9832Phase 2 ClinicalAbbvie IncArthritis, Rheumatoid
Details
RavagalimabABBV-323; PR-1629977Phase 2 ClinicalAbbvie IncColitis, Ulcerative; Sjogren's Syndrome
Details
DFI-105DFI105; DFI-105Phase 2 ClinicalDiabetes Free IncDiabetes Mellitus, Type 2
Details
SHR-2005SHR2005; SHR-2005Phase 2 ClinicalShanghai Hengrui Pharmaceutical Co LtdUrinary Bladder Neoplasms
Details
SV-102SV-102; SV102; SYNC-T SV-102Phase 2 ClinicalSyncromune IncProstatic Neoplasms, Castration-Resistant
Details
SHR-7367SHR7367; SHR-7367Phase 2 ClinicalShanghai Hengrui Pharmaceutical Co LtdNeoplasms; Solid tumours
Details
CifurtilimabSEA-1C10; SEA-CD40Phase 2 ClinicalSeagen IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Metastasis; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
TQB-2916TQB2916; TQB-2916Phase 2 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupMelanoma; Neoplasms; Pancreatic Neoplasms; Sarcoma
Details
MIL-97MIL-97Phase 2 ClinicalBeijing Mabworks Biotech Co LtdPancreatic Neoplasms; Solid tumours
Details
DalnicastobartLVGN7409; LVGN-7409Phase 2 ClinicalLyvgen Biopharma(HK)LtdCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Papillomavirus Infections; Sarcoma; Solid tumours; Stomach Neoplasms; Uveal melanoma
Details
OPT-101OPT-101Phase 2 ClinicalOp-T LLCDiabetes Mellitus, Type 1; Pneumonia; Sepsis
Details
2141-V112141-V11Phase 2 ClinicalThe Rockefeller UniversityGanglioglioma; Glioblastoma; Glioma; Neoplasms; Prostatic Neoplasms; Skin Neoplasms; Solid tumours; Urinary Bladder Neoplasms
Details
CiltistotugYH003; YH-003Phase 2 ClinicalCarcinoma, Pancreatic Ductal; Melanoma; Pancreatic Neoplasms; Solid tumours
Details
AbiprubartKPL-404Phase 2 ClinicalBeth Israel Deaconess Medical CenterArthritis, Rheumatoid; Sjogren's Syndrome
Details
NJA-730NJA-730; NJA-730a; NJA-730bPhase 1 ClinicalNapajen PharmaAutoimmune Diseases
Details
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine)Phase 1 ClinicalBaylor College Of MedicineLeukemia, Lymphocytic, Chronic, B-Cell
Details
GiloralimabABBV-927Phase 1 ClinicalAbbvie IncCarcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
NG-350ANG-350APhase 1 ClinicalAkamis Bio LtdNeoplasm Metastasis; Neoplasms, Glandular and Epithelial; Rectal Neoplasms
Details
SL-172154SL-172154; SIRPα -Fc-CD40LPhase 1 ClinicalShattuck Labs IncCarcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
recombinant adenovirus vector vaccine targeting MUC1 (MicroVax)Phase 1 ClinicalMicrovax LlcNeoplasms
Details
HIV ANTI-CD40.ENV GP140Phase 1 ClinicalLinKinVaxHIV Infections
Details
PeptiCRAd-1Valo-D102; PeptiCRAd-1Phase 1 ClinicalValor BiotherapeuticsCarcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms
Details
CD40xFAP bispecific antibody (Bristol-Myers Squibb Company)Phase 1 ClinicalBristol-Myers Squibb CompanySolid tumours
Details
M-0324M-0324; M0324Phase 1 ClinicalMerck KGaA, Darmstadt, GermanyNeoplasms; Solid tumours
Details
KK-2269KK-2269; KK2269Phase 1 ClinicalKyowa Kirin IncCarcinoma, Non-Small-Cell Lung; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms
Details
LNF-1901LNF-1901; LNF1901Phase 1 ClinicalLunan Pharmaceutical Group CoNeoplasms
Details
B-901B-901; B901Phase 1 ClinicalFutureGen Biopharm (Beijing) Co LtdSolid tumours
Details
SHR-1704SHR-1704Phase 1 ClinicalJiangsu Hengrui Medicine Co LtdNeoplasms
Details
IMB-071703IMB-071703; IMB071703Phase 1 ClinicalBeijng Immunoah Pharma Tech Co LtdSolid tumours
Details
ILB-2101ILB-2101Phase 1 ClinicalInnolake Biopharm (Hangzhou) Co LtdNeoplasms
Details
HBM-9027HBM-9027; HBM9027Phase 1 ClinicalHarbour BiomedNeoplasms; Solid tumours
Details
BSI-038BSI-038Phase 1 ClinicalBiosion IncSolid tumours
Details
RO-7300490RO-7300490; RG-6189; FAP-CD40; FAP-huCD40Phase 1 ClinicalF. Hoffmann-La Roche LtdSolid tumours
Details
InezetamabAMG-994Phase 1 ClinicalAmgen IncSolid tumours
Details
BMS-986325Y 12XX-hz28-P238KPhase 1 ClinicalBristol-Myers Squibb CompanySjogren's Syndrome
Details
NWY-001(Biocytogen Pharmaceuticals)NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals)Phase 1 ClinicalHematologic Neoplasms; Neoplasms; Solid tumours
Details

Avis sur les produits

  • Informations sur la molécule
  • Liste de produits
  • Avis sur les produits
  • Informations sur les médicaments cliniques